Casper Tax1, Maroeska M Rovers2, Corine de Graaf3, Petra L M Zusterzeel3, Ruud L M Bekkers3. 1. Radboud University Medical Centre, Radboudumc Institute for Health Sciences, Department of Operating Rooms, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands. Electronic address: Casper.Tax@radboudumc.nl. 2. Radboud University Medical Centre, Radboudumc Institute for Health Sciences, Department of Operating Rooms, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands; Radboud University Medical Centre, Radboudumc Institute for Health Sciences, Department of Health Evidence, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands. 3. Radboud University Medical Centre, Radboudumc Institute for Health Sciences, Department of Gynaecology, P.O. Box 9101, 6500 HB Nijmegen, the Netherlands.
Abstract
OBJECTIVE: Recent reviews on the sentinel lymph node (SLN) procedure in cervical cancer have shown that bilateral SLN detection and ultra staging are safe and superior options compared to a unilateral detection, frozen section and H&E analysis. So far, nobody identified a subgroup of patients in whom a SLN procedure may replace pelvic lymph node dissection (PLND). METHODS: We searched PubMed, Embase, CINAHL and Cochrane from inception up to November 26, 2014. Studies reporting SLN detection, and/or histological outcome of the SLN were included. Methodological quality was assessed with the Quality Assessment of Diagnostic Accuracy Studies tool by two independent reviewers. Data to complete 2×2 contingency tables were obtained, and patient-, study- and technique characteristics were extracted. Results were pooled and plotted in forest plots. RESULTS: Forty-seven studies (4130 patients) were analyzed. Pooled data of diagnostic accuracy on ultra staging (18 studies; 1275 patients) showed a sensitivity of 94% (95% CI 80-99%) and negative predictive values ranging between 91 and 100%. After ultra staging, 19 false negative results remained. Prerequisites such as early FIGO stage (IA2, IB1, IIA primary tumor size <40mm), no suspicious pre-, and per-operative lymph nodes, and bilateral negative SLNs after ultra staging resulted in 1 remaining false negative result among 1257 patients (0.08%). Pooled data on a combined tracer in early stage cervical cancer patients with primary tumor size <20mm (6 studies; 276 patients) resulted in 87% bilateral SLN detection. CONCLUSIONS: Early stage cervical cancer patients (FIGO IA2, IB1, IIA primary tumor size <40mm) who have no suspicious pre-, and per-operative lymph nodes, and have bilateral negative SLNs after ultra staging, have a residual risk of 0.08% (1/1257) on occult metastases. On the basis of these results we recommend not to perform a full PLND in these patients.
OBJECTIVE: Recent reviews on the sentinel lymph node (SLN) procedure in cervical cancer have shown that bilateral SLN detection and ultra staging are safe and superior options compared to a unilateral detection, frozen section and H&E analysis. So far, nobody identified a subgroup of patients in whom a SLN procedure may replace pelvic lymph node dissection (PLND). METHODS: We searched PubMed, Embase, CINAHL and Cochrane from inception up to November 26, 2014. Studies reporting SLN detection, and/or histological outcome of the SLN were included. Methodological quality was assessed with the Quality Assessment of Diagnostic Accuracy Studies tool by two independent reviewers. Data to complete 2×2 contingency tables were obtained, and patient-, study- and technique characteristics were extracted. Results were pooled and plotted in forest plots. RESULTS: Forty-seven studies (4130 patients) were analyzed. Pooled data of diagnostic accuracy on ultra staging (18 studies; 1275 patients) showed a sensitivity of 94% (95% CI 80-99%) and negative predictive values ranging between 91 and 100%. After ultra staging, 19 false negative results remained. Prerequisites such as early FIGO stage (IA2, IB1, IIA primary tumor size <40mm), no suspicious pre-, and per-operative lymph nodes, and bilateral negative SLNs after ultra staging resulted in 1 remaining false negative result among 1257 patients (0.08%). Pooled data on a combined tracer in early stage cervical cancerpatients with primary tumor size <20mm (6 studies; 276 patients) resulted in 87% bilateral SLN detection. CONCLUSIONS: Early stage cervical cancerpatients (FIGO IA2, IB1, IIA primary tumor size <40mm) who have no suspicious pre-, and per-operative lymph nodes, and have bilateral negative SLNs after ultra staging, have a residual risk of 0.08% (1/1257) on occult metastases. On the basis of these results we recommend not to perform a full PLND in these patients.
Authors: Gloria Salvo; Pedro T Ramirez; Charles F Levenback; Mark F Munsell; Elizabeth D Euscher; Pamela T Soliman; Michael Frumovitz Journal: Gynecol Oncol Date: 2017-02-08 Impact factor: 5.482
Authors: A de Juan; A Redondo; M J Rubio; Y García; J Cueva; L Gaba; A Yubero; J Alarcón; C Maximiano; A Oaknin Journal: Clin Transl Oncol Date: 2020-01-24 Impact factor: 3.405
Authors: Alessandro Buda; Jvan Casarin; Michael Mueller; Francesco Fanfani; Ignacio Zapardiel; Liliana Mereu; Andrea Puppo; Elena De Ponti; Marco Adorni; Debora Ferrari; Maria Luisa Gasparri; Fabio Ghezzi; Giovanni Scambia; Andrea Papadia Journal: J Cancer Res Clin Oncol Date: 2020-11-01 Impact factor: 4.553
Authors: Ilse G T Baeten; Jacob P Hoogendam; Arthur J A T Braat; Ronald P Zweemer; Cornelis G Gerestein Journal: EJNMMI Res Date: 2022-06-20 Impact factor: 3.434
Authors: Nadeem R Abu-Rustum; Roberto Angioli; Arthur E Bailey; Vance Broach; Alessandro Buda; Michelle R Coriddi; Joseph H Dayan; Michael Frumovitz; Yong Man Kim; Rainer Kimmig; Mario M Leitao; Mustafa Zelal Muallem; Matt McKittrick; Babak Mehrara; Roberto Montera; Lea A Moukarzel; Raj Naik; Silvana Pedra Nobre; Marie Plante; Francesco Plotti; Oliver Zivanovic Journal: Int J Gynecol Cancer Date: 2020-03-30 Impact factor: 3.437
Authors: Matthias Weissinger; Florin-Andrei Taran; Sergios Gatidis; Stefan Kommoss; Konstantin Nikolaou; Samine Sahbai; Christian la Fougère; Sara Yvonne Brucker; Helmut Dittmann Journal: J Nucl Med Date: 2021-01-28 Impact factor: 10.057
Authors: Sandra Russo; Joan L Walker; Jay W Carlson; Jeanne Carter; Leigh C Ward; Allan Covens; Edward J Tanner; Jane M Armer; Sheila Ridner; Sandi Hayes; Alphonse G Taghian; Cheryl Brunelle; Micael Lopez-Acevedo; Brittany A Davidson; Mark V Schaverien; Sharad A Ghamande; Michael Bernas; Andrea L Cheville; Kathleen J Yost; Kathryn Schmitz; Barbara Coyle; Jeannette Zucker; Danielle Enserro; Stephanie Pugh; Electra D Paskett; Leslie Ford; Worta McCaskill-Stevens Journal: Gynecol Oncol Date: 2020-11-04 Impact factor: 5.482